|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||19.45 - 19.50|
|52-week range||19.45 - 19.50|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||0.03|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Most readers would already be aware that uniQure's (NASDAQ:QURE) stock increased significantly by 52% over the past...
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.